Skip to content

Does Blue Cross Blue Shield FEP cover Wegovy, Zepbound and Saxenda?

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

FEP Blue covers Wegovy and Saxenda with prior approval, and covers Zepbound as a non-preferred drug. Blue Cross Blue Shield Federal Employee Program policy 5.99.030 allows Wegovy and Saxenda if you meet its BMI rules and have taken part in a comprehensive weight management program. Policy 5.99.031 treats Zepbound as non-preferred: two oral weight-management medicines and the preferred product must come first.

Key takeaways

  • FEP Blue needs prior approval for Wegovy, Saxenda and Zepbound.
  • Adults need a BMI of 30 or more, or 27 or more with established cardiovascular disease or a weight-related condition.
  • Zepbound comes after two oral weight-management medicines and the preferred product, unless a valid medical exception applies.
  • The first weight-management approval is 6 months. Adult renewal needs at least 5 percent loss of baseline body weight.
  • Once approved, ask FEP what you'd pay on your plan option. The policies don't state a tier or copay.

What the published policies say

  • Blue Cross Blue Shield Federal Employee Program: Saxenda fep covered with pa

    FEP Blue requires prior approval for Saxenda. It can be approved for chronic weight management in people 12 and older who meet the BMI rules and have taken part in a comprehensive weight management program.

    • Adults: BMI of 30 or more, or 27 or more with established cardiovascular disease or a weight-related condition
    • Ages 12 to 17: BMI at or above the 95th percentile for age
    • Participation in a comprehensive weight management program
    • No use together with another GLP-1 drug or another prior-approval weight-loss drug
    • Initial approval 6 months; renewal for 12 months requires at least 5 percent loss of baseline body weight in adults
    Saxenda and Wegovy may be considered medically necessary if the conditions indicated below are met. ... Patient has participated in a comprehensive weight management program (e.g., Teladoc or another weight loss program)

    5.99.030 Saxenda Wegovy

  • Blue Cross Blue Shield Federal Employee Program: Wegovy fep covered with pa

    FEP Blue requires prior approval for Wegovy. It can be approved for chronic weight management in people 12 and older (injection) or 18 and older (tablets), and Wegovy injection can also be approved for MASH in adults. The patient must have taken part in a comprehensive weight management program.

    • Adults: BMI of 30 or more, or 27 or more with established cardiovascular disease or a weight-related condition
    • Ages 12 to 17 (injection only): BMI at or above the 95th percentile for age
    • Participation in a comprehensive weight management program
    • No use together with another GLP-1 drug or another prior-approval weight-loss drug
    • Initial approval 6 months for weight management; renewal for 12 months requires at least 5 percent loss of baseline body weight in adults
    Saxenda and Wegovy may be considered medically necessary if the conditions indicated below are met. ... Patient has participated in a comprehensive weight management program (e.g., Teladoc or another weight loss program)

    5.99.030 Saxenda Wegovy

  • Blue Cross Blue Shield Federal Employee Program: Zepbound fep non preferred

    FEP Blue treats Zepbound as a non-preferred weight-loss drug that needs prior approval with supporting documentation. Adults must meet the BMI rules, have had an inadequate response to (or be unable to take) at least two oral weight-loss medicines, and have tried the plan's preferred product first unless there is a valid medical exception.

    • Age 18 or older
    • BMI of 30 or more, or 27 or more with established cardiovascular disease or a weight-related condition
    • Inadequate response, intolerance or contraindication to at least two oral weight-management medicines
    • Participation in a comprehensive weight management program
    • Must have tried the preferred product unless there is a valid medical exception
    • Initial approval 6 months; renewal for 12 months requires at least 5 percent loss of baseline body weight
    Zepbound may be considered medically necessary if the conditions indicated below are met. ... the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

    5.99.031 Zepbound

Policies differ between plans from the same insurer and change during the year. Your own plan documents decide.

The Blue Cross Blue Shield Federal Employee Program, known as FEP Blue, publishes its pharmacy policies in full. Two of them apply to the weight-loss GLP-1 medicines in our records: policy 5.99.030 for Saxenda and Wegovy, and policy 5.99.031 for Zepbound. FEP calls the process “prior approval.” It’s the same idea other insurers call prior authorization: the plan has to agree before it pays.

The short version: Wegovy and Saxenda are the easier requests, and Zepbound sits behind extra steps.

Wegovy and Saxenda: policy 5.99.030

Both can be approved for chronic weight management when you meet these rules:

  • Adults: a BMI of 30 or more, or 27 or more with established cardiovascular disease or a weight-related condition.
  • Ages 12 to 17: a BMI at or above the 95th percentile for age. For Wegovy, this applies to the injection only. Wegovy tablets are for ages 18 and older.
  • A weight program: the patient has taken part in a comprehensive weight management program. The policy’s own example is “Teladoc or another weight loss program.”
  • No doubling up: no use together with another GLP-1 drug or another weight-loss drug that needs prior approval.

Wegovy injection can also be approved for MASH, a liver condition, in adults under the same policy.

Zepbound: policy 5.99.031

FEP treats Zepbound as a non-preferred weight-loss drug, and the request needs supporting documentation. You have to be 18 or older and meet the same BMI rules. On top of that, the policy asks for:

  • An inadequate response, intolerance or contraindication (a medical reason you can’t take it) to at least two oral weight-management medicines.
  • Taking part in a comprehensive weight management program.
  • A trial of the plan’s preferred product first, unless the patient has what the policy calls “a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication).”

That’s step therapy, where the plan wants other medicines tried first, in two layers: oral medicines, then the preferred product, then Zepbound. If your prescriber believes you qualify for the medical exception, the request should say which exception applies and include the chart notes that show it.

How long approval lasts

For weight management, the first approval is 6 months under both policies. Renewal is for 12 months and, in adults, requires at least 5 percent loss of baseline body weight.

Things FEP members should check

The policies above set the clinical rules. They don’t state a tier or a copay, and drug lists and cost shares can differ between plan options. So ask FEP what you’d pay on your option once you’re approved.

If you’re also enrolled in Medicare, read our Medicare guide, because Medicare has its own rules for these medicines. Manufacturer savings cards exclude people enrolled in government funded programs, so read the card’s eligibility terms on the savings card page before you count on one.

Next steps

  1. Ask your prescriber to submit the prior approval request with your BMI, any weight-related conditions and proof of the weight management program.
  2. For Zepbound, add the record of the two oral medicines and the preferred product, or the medical exception. Our prior authorization checklist covers step therapy paperwork.
  3. If FEP says no, ask which criterion wasn’t met and follow the steps in appealing a denial. The appeal letter tool drafts the letter.

To see how FEP compares with other insurers, read the insurance guide. For what each drug costs outside insurance, see Wegovy and Zepbound.

Frequently asked questions

Does FEP Blue cover Wegovy for weight loss?

Yes, with prior approval. FEP policy 5.99.030 allows Wegovy for chronic weight management in people 12 and older for the injection, or 18 and older for the tablets. Adults need a BMI of 30 or more, or 27 or more with established cardiovascular disease or a weight-related condition. They must also have taken part in a comprehensive weight management program.

Does FEP Blue cover Zepbound?

Yes, as a non-preferred drug. FEP policy 5.99.031 requires prior approval with supporting documentation. Adults must meet the BMI rules and have had an inadequate response, intolerance or contraindication to at least two oral weight-management medicines. They must also have joined a comprehensive weight management program, and have tried the plan's preferred product unless there's a valid medical exception.

Can I take Wegovy with another GLP-1 on FEP Blue?

No. The policy for Saxenda and Wegovy doesn't allow use together with another GLP-1 drug or with another weight-loss drug that needs prior approval. If you're changing from one medicine to another, your prescriber's request should make clear that the first one has stopped.

How long does FEP Blue approve Wegovy or Zepbound for?

The first approval for weight management is 6 months under both policies. Renewal is for 12 months and, for adults, requires at least 5 percent loss of baseline body weight. Ask your prescriber to record your weight before your first dose, because renewal is measured against it.

Sources (2)

  1. 1.
    Blue Cross Blue Shield Federal Employee Program: 5.99.030 Saxenda Wegovy
    “Saxenda and Wegovy may be considered medically necessary if the conditions indicated below are met. ... Patient has participated in a comprehensive weight management program (e.g., Teladoc or another weight loss program)”
  2. 2.
    Blue Cross Blue Shield Federal Employee Program: 5.99.031 Zepbound
    “Zepbound may be considered medically necessary if the conditions indicated below are met. ... the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)”